Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
APLS 
Apellis Pharmaceuticals Inc (APLS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/02/2025: APLS (3-star) is a STRONG-BUY. BUY since 33 days. Simulated Profits (40.57%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
22 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $38.56
1 Year Target Price $38.56
| 10 | Strong Buy |
| 4 | Buy |
| 8 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 87.68% | Avg. Invested days 68 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 09/02/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.48B USD | Price to earnings Ratio - | 1Y Target Price 38.56 |
Price to earnings Ratio - | 1Y Target Price 38.56 | ||
Volume (30-day avg) 22 | Beta 0.77 | 52 Weeks Range 16.10 - 41.94 | Updated Date 09/1/2025 |
52 Weeks Range 16.10 - 41.94 | Updated Date 09/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.83 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -30.24% | Operating Margin (TTM) -18.65% |
Management Effectiveness
Return on Assets (TTM) -13.77% | Return on Equity (TTM) -108.49% |
Valuation
Trailing PE - | Forward PE 48.08 | Enterprise Value 3581543818 | Price to Sales(TTM) 4.61 |
Enterprise Value 3581543818 | Price to Sales(TTM) 4.61 | ||
Enterprise Value to Revenue 4.75 | Enterprise Value to EBITDA -12.12 | Shares Outstanding 126290000 | Shares Floating 78125464 |
Shares Outstanding 126290000 | Shares Floating 78125464 | ||
Percent Insiders 13.62 | Percent Institutions 105.71 |
Upturn AI SWOT
Apellis Pharmaceuticals Inc
Company Overview
History and Background
Apellis Pharmaceuticals, Inc. was founded in 2009. The company focuses on the discovery, development, and commercialization of therapeutic compounds for autoimmune and inflammatory diseases with high unmet medical needs. Key milestones include the development and approval of Empaveli and Syfovre.
Core Business Areas
- Complement Therapies: Apellis focuses on developing complement-targeted therapies for various diseases.
- Hematology: Develops treatments for hematologic diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH).
- Ophthalmology: Develops treatments for ophthalmologic diseases, especially geographic atrophy (GA).
Leadership and Structure
The leadership team includes Cedric Francois, M.D., Ph.D. (CEO), and various VPs heading R&D, commercial operations, and finance. The organizational structure is typical of a biotechnology company, with departments focused on research, clinical development, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- Empaveli (pegcetacoplan): Empaveli is a C3 inhibitor approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Competitors include Soliris (eculizumab) and Ultomiris (ravulizumab) from Alexion Pharmaceuticals (now part of AstraZeneca). Market share for Empaveli is growing but remains smaller than Alexion's products. It is difficult to have the market share or revenue.
- Syfovre (pegcetacoplan injection): Syfovre is the first approved treatment for geographic atrophy (GA) secondary to age-related macular degeneration. Competitors include Iveric Bio's Izervay (avacincaptad pegol). Market Share currently favors Apellis due to first-to-market advantage, though Iveric Bio will compete heavily. It is difficult to have the market share or revenue.
Market Dynamics
Industry Overview
The pharmaceutical industry, especially the segment focusing on complement-targeted therapies, is experiencing growth due to an increasing understanding of the role of the complement system in various diseases.
Positioning
Apellis is positioned as a leader in complement-targeted therapies, particularly in hematology and ophthalmology. Its competitive advantage lies in its innovative C3 inhibitor platform.
Total Addressable Market (TAM)
The TAM for geographic atrophy and paroxysmal nocturnal hemoglobinuria is estimated to be in the billions of dollars. Syfovre and Empaveli are positioned to capture a significant portion of this market.
Upturn SWOT Analysis
Strengths
- Novel C3 inhibitor platform
- First-mover advantage in GA treatment (Syfovre)
- Strong intellectual property protection
- Experienced management team
Weaknesses
- Reliance on a limited number of products
- Potential safety concerns with complement inhibition
- High R&D expenses
- Reimbursement challenges
Opportunities
- Expansion into new indications for complement-targeted therapies
- Strategic partnerships and collaborations
- Geographic expansion
- Advancements in drug delivery technologies
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent expirations
- Adverse events impacting product approval or sales
- Pricing and market access pressures
Competitors and Market Share
Key Competitors
- ALXN
- IVERIC Bio (ISEE)
Competitive Landscape
Apellis has a competitive advantage in the geographic atrophy market with Syfovre, being the first approved treatment. However, it faces competition from established players like Iveric Bio. Empaveli faces competition from Alexion's Soliris and Ultomiris.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by pipeline advancements and regulatory approvals.
Future Projections: Future growth is projected to be strong, driven by increased sales of Syfovre and Empaveli, and the development of new indications.
Recent Initiatives: Recent initiatives include expanding the commercial infrastructure for Syfovre and advancing clinical trials for new indications.
Summary
Apellis is a promising biotech company with innovative complement-targeted therapies, particularly in ophthalmology and hematology. The successful launch of Syfovre offers significant growth potential. However, the company faces competition, regulatory hurdles, and reimbursement challenges. Managing safety concerns and expanding the pipeline are crucial for sustained success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Press releases
- SEC Filings
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. The data provided is based on publicly available information and may not be entirely accurate or complete. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Apellis Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2017-11-09 | Co-Founder, President, CEO & Director Dr. Cedric Francois M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 705 | Website https://apellis.com |
Full time employees 705 | Website https://apellis.com | ||
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.